NASDAQ: VRXAVeraxa Biotech Holding Ag Stock
$2.30-0.61 (-20.96%)
Updated Jun 24, 2026
VRXA Price
$2.30
Fair Value Price
N/A
Market Cap
$325.24M
52 Week Low
$2.07
52 Week High
$27.36
P/E
-0.41x
P/B
-16.71x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$28.92k
Earnings
$6.74M
Gross Margin
N/A
Operating Margin
-286,029.75%
Profit Margin
-284,359.2%
Debt to Equity
-6.13
Operating Cash Flow
-$413k
Beta
0.39
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
VRXA Overview
Veraxa Biotech Holding AG is a clinical-stage biopharmaceutical company, formed via a merger with Voyager Acquisition Corp., focusing on developing next-generation cancer therapies such as antibody-drug conjugates (ADCs) and bispecific T-cell engagers. [64, 65]
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine VRXA's potential to beat the market
- VRXA doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important VRXA news, forecast changes, insider trades & much more!
VRXA News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how VRXA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
VRXA is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
VRXA is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
VRXA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more VRXA due diligence checks available for Premium users.
Valuation
VRXA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.41x
Industry
15.33x
Market
7.39x
VRXA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-16.71x
Industry
5.21x
VRXA's financial health
Profit margin
Revenue
$0.0
Net Income
$180.5k
Profit Margin
0%
VRXA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
VRXA's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$272.3M
Liabilities
$286.7M
Debt to equity
-18.69
VRXA's short-term liabilities ($8.17M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
VRXA's long-term liabilities ($111.08M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
VRXA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
VRXA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$149.3k
Investing
$0.0
Financing
$0.0
VRXA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
VRXA vs Biotech Stocks
Veraxa Biotech Holding Ag Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.